Europe Biobanking Market Report and Forecast 2024-2032

The global biobanking market size was valued at USD 72.1 billion in 2023, with Europe holding a significant market share. The market is driven by increasing investment in biomedical research. It is expected to grow at a CAGR of 6.60% during the forecast period of 2024-2032, with the values likely to attain USD 131.1 billion by 2032.

Key Takeaways

• Major funding initiatives are pivotal in establishing and expanding the biobank resources and are likely to boost the market share. In May 2023, the United Kingdom Biobank was reported to receive EUR 127.6 million in funding from the UK Research and Innovation (UKRI) to support its move to a new facility at Bruntwood SciTech’s Manchester Science Park.
• One of the significant Europe biobanking market trends is the rise in workflow automation in biobanking procedures to increase throughput as well as enable sample tracking and error reduction. For instance, in February 2023, a team of German researchers employed a robotic system to automate the isolation of peripheral blood mononuclear cells (PBMC) for biobanking samples.
• The International Agency for Research on Cancer (IARC) stated that the number of new cancer cases is projected to rise by 22.5% over the next two decades in Europe. Since biobanks play a crucial role in supporting research aimed at developing innovative treatments, the market size is likely to increase in the coming years.

Europe Biobanking Market Analysis

A biobank can be defined as a repository that collects, processes, stores, and distributes biological materials such as tissues, blood, and DNA, among others. In Europe, these biological samples and associated health data are increasingly utilized for medical research and diagnostic purposes. With the rising emphasis on translating scientific research into clinical applications coupled with the growing impetus towards the development of personalized medicine, the Europe biobanking market demand is expected to witness a surge in the forecast period.

The market is greatly influenced by substantial investments from government bodies and private organizations across Europe. In May 2023, the United Kingdom Biobank (large-scale biomedical database) was reported to receive EUR 127.6 million in funding from the national funding agency UK Research and Innovation (UKRI) to support its move to a new facility at Bruntwood SciTech’s Manchester Science Park. With improved technologies and capacity at the purpose-built facility, the UK Biobank is expected to drive innovation in healthcare research and open new opportunities for collaboration. Such major funding initiatives are pivotal in establishing and expanding the biobank resources and are likely to boost the Europe biobanking market growth.

One of the significant market trends is the rise in workflow automation in biobanking to increase output as well as offer sample tracking and error reduction. For instance, in February 2023, a team of German researchers employed a robotic system to automate the isolation of peripheral blood mononuclear cells (PBMC) for biobanking samples. The novel robotic system exhibited equivalent cell yield, composition, and viability, as compared to manual processing, revealing its potential as a robust tool for collecting high-quality clinical samples for biobanking in the hematology and immunology field. The integration of such technologies in the biobanking procedures is likely to ensure high-quality samples and data, thereby elevating the Europe biobanking market share.

The market is also influenced by the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, among others, in the region. According to the International Agency for Research on Cancer (IARC), the number of new cancer cases is projected to rise by 22.5% over the next two decades in Europe. As biobanks play a vital role in supporting research aimed at understanding the cause of disease and developing innovative treatments, the market value is likely to increase in the coming years.

Europe Biobanking Market Segmentation

Market Breakup by Product and Service

• Equipment
• Consumables
• Service
• Software

Market Breakup by Application

• Regenerative Medicine
• Life Science Research
• Clinical Research

Market Breakup by Sample Type

• Blood Tissue
• Nucleic Acids
• Cell Lines

Market Breakup by End User

• Academic Institutions
• Pharma and Biotech Companies

Market Breakup by Country

• United Kingdom
• Germany
• France
• Italy

Europe Biobanking Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• QIAGEN N.V.
• Merck KGaA
• Tecan Trading AG
• Greiner Holding AG
• Micronic
• BioKryo
• SPT Labtech
• ASKION GmbH
• Cell&Co BioServices
• CTIBiotech

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Europe biobanking market forecast outlook for 2024-2032?
Europe biobanking market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 6.89% during the forecast period of 2024-2032 and is likely to reach a market value of USD 131.1 billion by 2032.

What are the major factors aiding the Europe biobanking market demand?
The growing prevalence of chronic diseases and the increasing investment in biomedical research are fuelling the demand for the market.

What are the major Europe biobanking market trends?
One of the significant trends in the market is the rise in workflow automation in biobanking procedures to increase throughout as well as enable sample tracking and error reduction. For instance, in February 2023, German researchers employed a robotic system to automate the isolation of peripheral blood mononuclear cells (PBMC) for biobanking samples.

What is the market segmentation based on the product and services?
Based on the products and services, the market is segmented into equipment, consumables, services, and software.

What is the market breakup by sample type?
By sample type, the market is divided into blood tissue, nucleic acids, and cell lines.

What are the major end users of biobanking?
End users of the market are academic institutions, along with pharma, and biotech companies.

What are the applications of biobanking?
Major applications include regenerative medicine, life science research, and clinical research.

What is the market segmentation by countries?
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy.

Who are the key players involved in the Europe biobanking market?
The key players in the market are QIAGEN N.V., Merck KGaA, Tecan Trading AG, Greiner Holding AG, Micronic, BioKryo, SPT Labtech, ASKION GmbH, Cell&Co BioServices, and CTIBiotech.


This product will be delivered within 5-7 business days.